Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon-Reference-Cited by-同舟云学术

Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon

Published:2023-01-03 Issue:4 Volume:77 Page:1074-1077
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:

Author:

Cabibbo Giuseppe¹^ORCID,Celsa Ciro¹²^ORCID,Alimenti Eleonora³^ORCID,Iavarone Massimo⁴^ORCID

Affiliation:

1. Section of Gastroenterology & Hepatology, Department of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy

2. Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy

3. Department of Medical Sciences, University of Pavia, Pavia, Italy

4. Division of Gastroenterology and Hepatology, IRCCS Foundation, Ca'Granda Ospedale Maggiore Policlinico of Milan, Milan, Italy

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Reference16 articles.

1. Inborn/outborn status and neonatal survival: a meta-analysis of non-randomized studies;Ozminkowski;Stat Med,1988

2. Outcome of patients with hepatocellular carcinoma and liver dysfunction under immunotherapy: a Systematic review and meta-analysis;El Hajra;Hepatology,2023

3. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkMate 040 randomized clinical trial;Yau;JAMA Oncol,2020

4. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial;Zhu;Lancet Oncol,2018

5. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA;Abou-Alfa;J Clin Oncol,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment;Hepatology;2024-07-19

2. Efficacy and safety of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk;Frontiers in Oncology;2024-07-15